Latest News

Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.

According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.

According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...

Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...

A safety lead-in for the STARBOARD trial found that both doses of encorafenib under evaluation, in combination with binimetinib and pembrolizumab, demonstrated safety that was comparable to the known profile for each agent.

A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.

According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.

Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.

The FDA granted accelerated approval to asciminib for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.

Results from the phase 2 RAMOSE study demonstrated that the addition of ramucirumab to osimertinib significantly prolonged progression-free survival for patients with TKI-naive EGFR-mutated metastatic non-small cell lung cancer.